Natural history and long-term outcome of patients treated for early stage colorectal cancer

Hugh James Freeman MD CM FRCPC

BACKGROUND: The long-term natural history of early stage colon cancer and the outcome of long-term colonoscopic surveillance in routine specialist clinical practice after removal of the incident cancers have not been fully defined. In the present long-term evaluation up to 25 years, metachronous neoplasia, including both advanced adenomas and carcinomas, was defined.

METHODS: All early stage colorectal cancer patients evaluated consecutively from a single clinical practice underwent follow-up colonoscopic evaluations after removal of the incident cancer and clearing of neoplastic disease. Colonoscopic surveillance was planned for two phases – initially on an annual basis for five years, followed by continued surveillance every three years up to 25 years with removal of any metachronous neoplastic lesion.

RESULTS: A total of 128 patients (66 men and 62 women) with 129 incident early stage colorectal cancers were evaluated. Virtually all patients were symptomatic, usually with clinical evidence of blood loss. Incident early cancers were located throughout the colon, especially in the rectosigmoid, and showed no pathological evidence of nodal or other metastases. All patients evaluated during the first five years did not experience recurrent disease or have metachronous cancer detected. After five years, a total of 94 patients were evaluated up to 25 years; six of these patients were found to have seven metachronous colon cancers. All developed cancer more than seven years after removal of the incident colorectal cancer, including six asymptomatic adenocarcinomas, of which only one had evidence of single node involvement. Another patient in this cohort developed a poorly differentiated neuroendocrine carcinoma of the colon. In addition, 45% of patients had a total of 217 adenomas removed, including 11% of patients with 33 advanced adenomas. Among 14 patients with advanced adenomas, seven (50%) developed ≥2 late metachronous cancers.

CONCLUSIONS: Following removal of an incident symptomatic early stage colorectal cancer, the risk of later metachronous neoplasia persists for an extended period more than five years after removal of the incident colorectal cancer. Moreover, risk for late metachronous cancer appears to be predicted by the presence of multiple adenomas or advanced adenomas; most metachronous cancers in this cohort were detected using colonoscopy before onset of symptoms and at an early stage.

Key Words: Advanced adenoma; Colon cancer; Colon polyps, Colonoscopic polypectomy; Metachronous colon cancer; Natural history; Synchronous colon cancer

Most patients with colorectal cancer have localized or locally advanced disease, usually leading to a ‘curative’ resection (1). Later follow-up now includes colonoscopic review guided by updated expert recommendations (2). Because the prognosis for recurrent disease has been disappointing, colonoscopic evaluations in this setting have largely focused on detection of metachronous neoplasms (2).

In extended studies of stage 2 or 3 colorectal cancer, a second primary or metachronous cancer has been estimated to develop in up to 6.3% of patients (3-5), while adenomas were recorded in approximately 50% (6,7). The National Polyp Study (8) established a definite benefit for colonoscopic polypectomy to prevent colorectal cancer, although only adenoma patients, rather than cancer patients, were included. Recently, prevention of deaths attributed to colorectal cancer was also reported after colonoscopic removal of adenomas in these patients (9).

Intervals for colonoscopic surveillance after curative resection of a colorectal cancer remain controversial; however, current guidelines...
have recommended that initial follow-up should be more intense in the first five years to exclude missed synchronous cancers or early metachronous neoplasms, particularly in individuals with multiple or large neoplastic lesions. A number of randomized, but historical, trials from surgical centres have compared intense with less intense surveillance after a ‘curative’ resection. Unfortunately, a number of methodological flaws in these studies were noted (1), particularly the inclusion of both early (ie, ‘node-negative’) and late (ie, ‘node-positive’) stage disease together in the different groups being compared, regardless of the intensity of subsequent follow-up. Evaluation of more homogeneous populations, particularly with early stage disease, would have been optimal because the prognosis for patients with nodal involvement, invasion of other structures and distant metastases is more guarded. Although a survival benefit with intense follow-up has been established (16), longer-term data from such high-risk populations more than five years following colorectal cancer resection remain limited.

The present study focused on early stage colorectal cancer patients without evidence of nodal involvement or other metastases. Consecutive patients were evaluated for up to 25 years during the course of a single clinical practice experience to detect recurrent cancer or any new metachronous neoplasms, including second (or more) colorectal cancers.

METHODS

Patient population

All patients diagnosed with early stage ‘sporadic’ colorectal cancer by the investigator during a 25-year period from July 1980 to June 2005 were consecutively evaluated with the total follow-up period progressing for up to 25 years to June 2010. Before treatment, all patients underwent standard laboratory tests including a hemogram, liver chemistry tests and carcinoembryonic antigen (CEA) determination. In addition, radiological imaging studies, including computed tomography (CT) scanning, were completed. All patients had colorectal cancer established by a pathologist with expertise in diagnosis and pathological staging of colon cancer using an established classification method (TNM system, American Joint Committee on Cancer). Patients with a perforating cancer or metastatic disease, including those with lymphatic invasion or lymph node involvement, adherence to adjacent structures or invasion into adjacent or peripheral structures, were excluded from the present evaluation even if a ‘curative’ surgical resection was performed.

Early stage colorectal cancer was defined on the basis of pathological assessment of the resected colon and lymph nodes; however, some patients were treated only with colonoscopic polypectomy and have been reported in detail elsewhere (17). In these polypectomy patients, lymph nodes could not be examined unless a further surgical resection was performed to ensure complete excision (based on a 2 mm clearance margin from the cautery margin for malignant polyps). In all patients, CEA studies were normal and CT scanning showed no evidence of lymph node or metastatic disease.

Exclusion criteria also included a personal or familial history of inflammatory bowel disease, including either ulcerative colitis or Crohn disease, or a previous family history of colon neoplasia including colorectal polyps or colorectal cancer.

Colonoscopic evaluations

All patients underwent a ‘clearing’ colonoscopy usually before cancer resection or, in some, within six months of cancer removal. Subsequently, annual colonoscopy was planned for the next five years with removal of visualized polyps and, if colonoscopy failed to reveal any neoplastic disease at the five-year colonoscopy, additional colonoscopies were subsequently scheduled every three years. If neoplastic disease was detected at the five-year colonoscopy, annual colonoscopic evaluation was planned until no neoplastic disease was detected, and colonoscopies were subsequently planned for every three years. Cessation of follow-up after completion of this initial five-year period was arbitrary but was offered to each patient depending on clinical assessment related to age, patient desire to continue as well as development of other concomitant comorbidities (eg, other malignancies, significant cardiopulmonary disease, dementia).

All patients underwent colonoscopies and removal of all visualized polyps after a standard bowel preparation was completed; a consent form for colonoscopy and polypectomy was signed before each procedure. This approval also specified that any information generated from these procedures could also be used for quality assurance review, including medical reporting. Most patients were administered a combination of intravenous sedative and narcotic before the procedure; some requested that the procedure be performed without medication.

Over the extended period of the present study, both standard and high-definition colonoscopes were used. At each colonoscopy, the size and location of each neoplastic polyp was defined and removed, with pathological evaluation performed to confirm the presence of neoplastic change (adenoma, tubulovillous adenoma, villous adenoma). Biopsies were also routinely obtained during each colonoscopy from the surgical anastomoses to exclude any microscopic recurrent cancer.

Definitions

Synchronous colon cancer was defined as a second colon cancer detected at the time of the initial colon cancer diagnosis, while metachronous colon cancer was defined as any subsequent colon cancer detected during the follow-up period. Neoplastic polyps (tubular adenoma, tubulovillous adenoma, villous adenoma) were also defined as advanced polyps based on one or more of the following criteria: size >1 cm; pathological detection of villous components; or severe dysplasia (10).

End dates of evaluations and statistical analysis

Each patient was considered to have ‘complete’ data for the initial five-year period if four colonoscopies were performed within the first five years of follow-up after the incident colorectal cancer was resected. A patient completing fewer than four colonoscopies in the initial five-year period was considered to have ‘incomplete’ data. After five years, only patients from the initial five years up to the end of the study in June 2010 were included. Statistical analyses were performed using χ² or the Student’s t test.

RESULTS

Patient sex, age and race

A total of 128 patients with a pathologically confirmed diagnosis of colorectal adenocarcinoma, defined as early colorectal cancer, were evaluated in the present long-term study. The entire study cohort is represented in Figure 1, based on age at diagnosis of colorectal cancer. Most men and women in the present evaluation were 50 to 70 years of age. There were 66 men (51.6%), mean age 65.5 years; median age 62 years), and 62 women (mean age 64.8 years; median age, 62 years) ranging in age from 29 to 86 years at the time of initial diagnosis of early stage colon cancer. Of these, 114 patients (89.1%), were Caucasian. There were also 13 Asian patients (seven male and six female) and one First Nations male.

While familial or inherited cases of colon cancer were excluded, the present evaluation included an otherwise healthy married couple (ie, ‘marital colon cancer’ – an 86-year-old man with a stage 1 cecal cancer (T1N0M0) and a 74-year-old woman with a stage 1 sigmoid cancer (T1N0M0). The woman was initially diagnosed in 2005 after presenting with rectal bleeding, followed by her asymptomatic husband later in the same year, referred for a screening procedure. Both later completed an additional five years of planned follow-up.

Symptoms with incident and metachronous colon cancer

All patients, except for the asymptomatic man noted above, were diagnosed with the initial colon cancer after presentation with one or more symptoms. A total of 96 (75%) patients had evidence of colonic blood loss, usually as intermittent rectal bleeding, occult blood-positive stools or iron deficiency-associated anemia. In some, this was associated with
chronic use of an anticoagulant medication, specifically, warfarin. A total of 37 (29%) patients described poorly localized abdominal pain or discomfort, while 29 (23%) reported a change in bowel habit, either diarrhea, constipation or increased stool frequency.

All patients later found to have a metachronous colon adenocarcinoma were asymptomatic, while one patient with intermittent abdominal pain and diarrhea during and after foreign travel in Europe, and previously reported (18), experienced a later neuroendocrine carcinoma of the colon.

**Incident colon cancers**

Of 129 incident colon cancers detected in 128 patients (one 38-year-old woman with two synchronous colon cancers in the descending colon, both T1N0M0), all were adenocarcinomas. For this cohort, the majority (n=82 [63%]) of incident early colorectal cancers were localized in the rectosigmoid, while 13 (10%) were localized in the descending colon and six (5%) in the transverse colon. The remaining 28 (22%) were localized in the right colon (cecum and ascending colon). If the rectosigmoid and descending colon cancers were classified as left colon, most early colorectal cancers in this cohort (i.e., >75%) were located there, significantly greater than the number of early colon cancers in the right colon, specifically cecum and ascending colon (P<0.05). The sex distributions for each of these colon sites (i.e., rectosigmoid, descending colon, transverse colon, right colon (cecum and ascending colon) were similar.

Pathology of the resected specimens noted that all incident early colorectal cancers were well-differentiated or moderately differentiated adenocarcinomas. In addition, mucinous components were noted in five of 28 (approximately 18% of right-sided colon cancers) and three of nine (3%) colorectal cancers in the sigmoid or descending colon (P<0.05). Of 129 cancers in the 128 patients with early stage colorectal cancer, 68% of right-sided colon cancers were reported to extend into the muscularis propria, not significantly different from 55% of cancers in the descending colon and rectosigmoid. No differences were noted between men and women.

**Treatment of incident early colorectal cancers**

Of the 128 patients, 103 (>80%) underwent resection for their cancer. The other 25 were treated with colonoscopic polypectomies using snare cautery; however, five of these 25 (20%) required an additional colon resection to ensure complete removal of the incident colon cancer. The other 20 patients treated with colonoscopic polypectomy did not undergo additional surgical resective treatment because the cautery margin was pathologically assessed to be >2 mm from the cancer margin. Of the five who underwent further resective surgery, only one had a focus of neoplastic cells localized within the submucosa in the resected colon surgical specimen that had not extended into the muscularis propria. All procedures in this selected cohort of 128 early colorectal cancer patients were considered to be ‘curative’ and no other adjuvant therapies were provided.

**Patient follow-up during the initial five years**

A total of 124 of 128 (97%) of patients completed the initial five-year follow-up phase with at least four or five colonoscopies evaluations each. In 124 of these, the final colonoscopy was scheduled and completed in the fifth year of follow-up. Collectively, 590 colonoscopies were satisfactorily completed without any procedure-related complications, including perforation or bleeding. No patient in this cohort of 128 was found to have macroscopic or histological evidence of recurrent cancer. Among the patients lost to follow-up (incomplete data) during the initial five years, there were two men – age 69 years (diagnosis, T2, 1997) and 77 years (diagnosis, T1, 2005) – each with follow-up data for three years after the initial colon cancer diagnosis, and two women – age 85 years (diagnosis, T3, 2002) and 83 years (diagnosis, T1, 2000) – with two years and three years, respectively, of completed follow-up data available. None of these four patients demonstrated evidence of recurrent colon cancer. The first man died suddenly in a private single passenger airplane accident following his third colonoscopy while the second man developed a neuroendocrine carcinoma of the bladder following his third colonoscopy, which led to an end to further colonoscopic evaluations and his death from the bladder cancer two years later. The first woman was lost to follow-up after her second annual review and colonoscopy, while the second woman underwent three subsequent colonoscopies evaluations but refused further follow-up evaluations.

**Patient follow-up after five years**

Of the 124 patients who completed the first five years of follow-up after the initial cancer resection, 94 (almost 80%) were evaluated from six to 25 years. The mean duration of follow-up was 11.7 years from the cancer resection. After the initial five-year period, an additional 351 colonoscopies were satisfactorily completed without any procedure-related complications, including perforation or bleeding. Figure 2 illustrates the patients seen from six to 25 years of follow-up. A total of 30 were not evaluated beyond five years due to patient preference, advanced age with or without other significant comorbidities. Of 94 patients evaluated after five years, 38 were followed for a total of six to nine years, 32 for 10 to 14 years, 18 for 15 to 19 years, and six for >20 years before the conclusion of the present study. Of these six patients, one was evaluated for 25 years.

This cohort of 94 patients evaluated for 26 years consisted of 47 men (mean age 60.7 years; median age 62 years) and 47 women (mean age 58.2 years; median age 61 years), who ranged in age from 29 to 81 years at the time of initial diagnosis of early stage colon cancer. Thus, 19 men and 15 women were not evaluated after five years (including two men and two women originally lost to follow-up in the first five years). Figure 3 reports the age ranges of men and women in this final cohort of 94 patients. As shown, and as might be expected, most patients who did not continue with ongoing evaluations after five years were elderly, age ≥70 years, with only 20 of the original 41 (<50%), for these two elderly age groups. For site distribution in this final cohort, a total of 14 of 29 patients with an incident right colon cancer (cecum and/or ascending colon ≤50% for this site) continued with more than five years of follow-up. All other sites each had at least two-thirds of the original cohort with continued follow-up for >5 years.

**Synchronous and metachronous colon cancers**

Of the 128 patients, a single 38-year-old woman had synchronous colon cancers in two sites on the initial colonoscopy (i.e., synchronous colon cancer detection rate <1%). These were located approximately 3 cm apart in the descending colon. Both cancers were pathologically confirmed as early stage colon cancers in the resected colon specimen (both T1 only).
During their follow-up evaluations, six other patients (approximately 5%) were later discovered to have seven metachronous colon cancers (including five men with six cancers). These are detailed further in Table 1, and all of these were surgically resected. One woman and one man also received added chemotherapy. Of these seven cancers, six were reported as well-differentiated or moderately well-differentiated adenocarcinomas. All of these adenocarcinomas were asymptomatic, being detected during colonoscopic evaluation ≥7 years after the initial colon cancer was defined. In a woman treated with added chemotherapy, single-node involvement was detected with a cecal cancer. In one man, intermittent diarrhea initially developed during foreign travel in Europe, and a poorly differentiated neuroendocrine carcinoma in the ascending colon with liver metastases was detected >20 years after the initial colon cancer resection. Of note, after his resection of the incident colorectal cancer, he was treated in the interval for prostate cancer and, later, a B cell lymphoma with a chemotherapy regimen that included added rituximab, a B cell-depleting monoclonal agent (18). In addition to resection of his second colon cancer, he was treated with chemotherapy using a cis-platinum-based regimen. In one other man, there were two metachronous colon cancers. These appeared seven and 13 years after the initial colon cancer was diagnosed and resected. Thus, in the 128 patients in the present study, a total of 135 colon cancers were detected, including a single poorly differentiated colonic neuroendocrine carcinoma.

Of note, one woman later developed a fatal small intestinal adenocarcinoma 10 years after the initial colon cancer was resected. No other gastric or intestinal malignancies were detected; however, one woman also demonstrated a 1 cm to 2 cm pancreatic cystic neoplasm on her initial CT scan. Annual imaging studies have not defined any significant change in size in the pancreatic lesion over five years.

Other colorectal neoplastic lesions
Collectively, there were a total of 217 adenomas resected in 128 patients; 33 (approximately 15%) could be classified as advanced adenomas as noted elsewhere (10). Most adenomas (124 of 217 [>50%]) were removed >5 years after the initial colon cancer resection. Of note, after his resection of the incident colorectal cancer, he was treated in the interval for prostate cancer and, later, a B cell lymphoma with a chemotherapy regimen that included added rituximab, a B cell-depleting monoclonal agent (18). In addition to resection of his second colon cancer, he was treated with chemotherapy using a cis-platinum-based regimen. In one other man, there were two metachronous colon cancers. These appeared seven and 13 years after the initial colon cancer was diagnosed and resected. Thus, in the 128 patients in the present study, a total of 135 colon cancers were detected, including a single poorly differentiated colonic neuroendocrine carcinoma.

Another woman developed a small bowel adenocarcinoma that was resected. In addition, 13 of these 14 patients had multiple adenomas and 10 had multiple advanced adenomas. Finally, a total of 103 adenomas were removed from these 14 patients, corresponding to 47.5% of all of the adenomas detected and removed in this cohort.

**Table 1**

<table>
<thead>
<tr>
<th>Age, years/sex</th>
<th>Year Dx for incident CA</th>
<th>Site-stage</th>
<th>Year Dx for metach CA</th>
<th>Site-stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>72/male*</td>
<td>1997</td>
<td>Sigmoid-T3</td>
<td>2004</td>
<td>Descending-T2</td>
</tr>
<tr>
<td>72/male</td>
<td>1990</td>
<td>Cecum-T3</td>
<td>2003</td>
<td>Sigmoid-T1</td>
</tr>
<tr>
<td>62/male</td>
<td>1988</td>
<td>Transverse-T3</td>
<td>1996</td>
<td>Cecum-T3</td>
</tr>
<tr>
<td>61/female</td>
<td>1997</td>
<td>Sigmoid-T1</td>
<td>2006</td>
<td>Cecum-T3†</td>
</tr>
<tr>
<td>61/male</td>
<td>1991</td>
<td>Sigmoid-T1</td>
<td>1999</td>
<td>Cecum-T1</td>
</tr>
<tr>
<td>58/male</td>
<td>1991</td>
<td>Sigmoid-T2</td>
<td>2011</td>
<td>Ascending‡</td>
</tr>
</tbody>
</table>

*Another metachronous cancer diagnosed (Dx) 2010 in the cecum (T3); †Cecal cancer with one of 12 resected lymph nodes positive; ‡Advanced neuroendocrine carcinoma involving lymph nodes and liver. CA Colon cancer; Metach Metachronous; TNM classification: T1, T2, T3; unless noted below, all N0M0

**Table 2**

<table>
<thead>
<tr>
<th>Age, years/sex</th>
<th>Adenomas</th>
<th>&lt;5 years</th>
<th>&gt;5 years</th>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>62/female</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>72/male</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>DC and cecum</td>
</tr>
<tr>
<td>67/male</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>74/male</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>42/female</td>
<td>4</td>
<td>0</td>
<td>2</td>
<td>Small bowel</td>
</tr>
<tr>
<td>65/male</td>
<td>11</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>29/male</td>
<td>8</td>
<td>1</td>
<td>2</td>
<td>Sigmoid</td>
</tr>
<tr>
<td>58/male</td>
<td>8</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>58/male</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>Neuroendo</td>
</tr>
<tr>
<td>68/male</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>62/male</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>Cecum</td>
</tr>
<tr>
<td>38/female</td>
<td>26</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>61/female</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>Cecum</td>
</tr>
<tr>
<td>61/male</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>Cecum</td>
</tr>
</tbody>
</table>

DC Descending colon; Neuroendo Neuroendocrine carcinoma
DISCUSSION
The present study explored the long-term natural history of symptomatic early (‘node-negative’) colorectal cancer after resection. End points for evaluation included detection of recurrent cancer, synchronous cancer, metachronous cancer and adenomas, including advanced adenomas. In contrast to previous historical reports describing significant rates of cancer recurrence (despite intense annual surveillance) in patients with different stages of the disease (3-6), the present evaluation found no recurrent disease. This is not surprising because the present cohort was highly selected, representing a more homogeneous early stage colorectal cancer population than earlier studies with no local or distant metastases, or nodal involvement. The patients in the present study, however, remained at high risk for later metachronous neoplasms, including both advanced adenomas and new metachronous colon cancers.

Seven new metachronous colorectal cancers developed late in six patients, after the initial five years of surveillance. In these patients, cancers developed seven years to >20 years following resection of the incident colon cancer. All of these patients had their initial studies performed for symptomatic disease, while all six metachronous adenocarcinomas were asymptomatic and only discovered by colonoscopic evaluation. Interestingly, most incident colon cancers (including patients with late developing metachronous cancers) were located in the sigmoid colon compared with metachronous colon cancers, which were usually detected in the ascending colon and cecum. Finally, the findings in the present study also contrast with a previous surgical centre report noting that metachronous colorectal cancers tend to appear at a later TNM stage than incident colorectal cancers (19). In the present report, most metachronous colon adenocarcinomas were detected at an early rather than a late TNM stage, even though one patient with a previous malignant sigmoid polyp had already developed a localized single node involvement from a metachronous cecal cancer. This may have been a late interval cecal cancer detected in the eighth year of follow-up, three years after her last colonoscopy following removal of a malignant sigmoid polyp, as reported elsewhere (20).

Even this patient, however, was asymptomatic amenable to a further ‘curative’ resection and adjuvant chemotherapy. Subsequent blood studies, including CEA testing, CT scans and two additional colonoscopies have been normal. In the present evaluation, detection of metachronous neoplasms was not limited to malignant lesions. Not surprisingly, given the extended duration of colonoscopic surveillance studies, the number of adenomas, including advanced adenomas, was significant. Collectively, approximately 45% of patients had adenomas and 11% had advanced adenomas detected and removed during follow-up after resection of the incident cancer.

Importantly, most of these adenomas, including advanced adenomas, were discovered >5 years after the original resection during a period of less-intense follow-up. In this selected group with early incident colorectal cancer, extended periods, even life-long follow-up after five years may be indicated to exclude both metachronous cancers and adenomas, including higher-risk advanced adenomas.

The present study did not evaluate guidelines for surveillance colonoscopy in patients with previous colon cancer. In fact, during the course of the present evaluation, the guidelines have evolved. To some degree, the present study supports current postresection guidelines for an increased intensity for colonoscopy surveillance, at least in the initial five years following surgical treatment. However, the present report also extends important observations of others to optimize outcomes (20), especially five years or more after removal of the incident colon cancer. Among patients in the present evaluation who eventually developed a metachronous cancer, all had a pre-existent phenotype including either multiple adenomas, advanced adenomas or both. In fact, in the present cohort, 50% of patients with multiple adenomas or advanced adenomas eventually developed a metachronous cancer, which was usually asymptomatic and at an early stage. These appeared to represent a special high-risk group, warranting consideration for more intense follow-up regardless of the duration following the initial colon cancer removal.

REFERENCES